CN106727369B - Dequalinium chloride buccal tablet and preparation method thereof - Google Patents
Dequalinium chloride buccal tablet and preparation method thereof Download PDFInfo
- Publication number
- CN106727369B CN106727369B CN201611042007.5A CN201611042007A CN106727369B CN 106727369 B CN106727369 B CN 106727369B CN 201611042007 A CN201611042007 A CN 201611042007A CN 106727369 B CN106727369 B CN 106727369B
- Authority
- CN
- China
- Prior art keywords
- dequalinium chloride
- buccal tablet
- mannitol
- sucrose
- dequalinium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Abstract
The invention belongs to the technical field of medicines, and particularly relates to a dequalinium chloride buccal tablet and a preparation method thereof. The dequalinium chloride buccal tablet comprises the following components: 80-95 parts of cane sugar, 1.5-2.5 parts of mannitol, 0.15-0.4 part of stearic acid, 0.005-0.01 part of pigment, 0.01-0.025 part of dequalinium chloride, 0.3-0.5 part of liquorice fluid extract, 0.002-0.004 part of methyl p-hydroxybenzoate, 1-3 parts of gelatin, 0.1-0.3 part of menthol, 0.1-0.3 part of essence, 0.1-0.35 part of magnesium stearate and 0.5-1.5 parts of sodium carboxymethylcellulose. The dequalinium chloride buccal tablet has the advantages of long dissolving time, good taste and lasting drug effect.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a dequalinium chloride buccal tablet and a preparation method thereof.
Background
Dequalinium chloride, also known as dequalinchloramine, is a white or milky powder, odorless, bitter in taste, readily soluble in boiling water, and easily deteriorated by light. Dequalinium chloride is a broad-spectrum antibacterial drug used for formulation of pharyngolaryngitis, oral cavity disinfection and the like.
The dequalinium chloride buccal tablet is a pressed tablet which can be contained in oral cavity and slowly dissolved, can produce relatively lasting drug effect on oral cavity and pharynx, and is used for local inflammation diminishing, disinfection and the like. The dequalinium chloride buccal tablet is popular with patients due to convenient taking and good taste. Due to slow buccal administration, the medicine can stay in pharynx for a long time to exert the drug effect continuously.
However, the buccal tablet of dequalinium chloride in the prior art has short buccal time, so that the patient needs to take the medicine very frequently and take the medicine again, which is not only unfavorable for the continuous exertion of the medicine effect, but also brings inconvenience to the patient due to the frequent taking of the medicine; in addition, after the dequalinium chloride buccal tablets sold at present are taken in mouth for a period of time, a non-greasy and astringent poor mouthfeel is usually generated, the poor mouthfeel is provided for a user, the feeling of conflict in taking is easily caused, and therefore the dequalinium chloride buccal tablets are difficult to accept by the patient and are not beneficial to popularization.
Disclosure of Invention
The invention aims to overcome the defects of the dequalinium chloride buccal tablet and provides a novel dequalinium chloride buccal tablet. The dequalinium chloride buccal tablet has longer buccal time and more lasting drug effect, reduces the frequency of taking medicine by a patient, and can treat throat or oral diseases more efficiently; in addition, the dequalinium chloride buccal tablet has excellent taste, does not have the feeling of non-greasiness and unsmooth after being taken in the mouth, gives better taste to patients, improves the taking compliance, is more easily accepted by the patients, and has wide market prospect.
In order to solve the technical problems, the invention adopts the following basic ideas:
a dequalinium chloride buccal tablet comprises the following components:
the dequalinium chloride buccal tablet prepared by the technical scheme has the advantages that the retention time in the oral cavity is long, the dequalinium chloride buccal tablet is not easy to break after being contained in the oral cavity, the drug effect is more durable, the taste is excellent, the non-greasy and non-astringent taste is avoided, and the compliance is good.
In order to obtain the beneficial effects which are relatively better or more excellent, the inventor carries out optimization experiments, and obtains the following preferable or more preferable technical scheme:
preferably, the dequalinium chloride buccal tablet consists of the following components:
more preferably, the dequalinium chloride buccal tablet consists of the following components:
preferably, the particle sizes of the sucrose, the mannitol and the dequalinium chloride are all 100-130 mu m.
More preferably, the particle sizes of the sucrose, the mannitol and the dequalinium chloride are all 110-120 mu m.
When the particle sizes of the sucrose, the mannitol and the dequalinium chloride are 100-130 mu m, the dissolving speeds of all the prescriptions in the oral cavity can be equivalent, and the phenomenon that the surface of the lozenge is slightly pitted due to different dissolving speeds of all the prescriptions to generate non-greasy and astringent taste is avoided, so that the taste of the dequalinium chloride lozenge is improved. Wherein, when the grain diameters of the sucrose, the mannitol and the dequalinium chloride are all 110-120 mu m, the effect of improving the taste is better.
Preferably, the dequalinium chloride buccal tablet further comprises 0.005-0.015 weight part of beta-cyclodextrin.
The beta-cyclodextrin added in parts by weight can relatively prolong the time of the dequalinium chloride buccal tablet in the oral cavity, and can further lighten the bitter taste of the dequalinium chloride buccal tablet, improve the taste and make a user more compliant.
Another important object of the present invention is to provide a method for preparing the dequalinium chloride buccal tablet, which comprises the following steps:
(1) weighing sucrose, mannitol, stearic acid and pigment in the formula parts, crushing, and fully and uniformly mixing;
(2) weighing gelatin and methyl p-hydroxybenzoate according to the prescription amount, adding water for dispersion, heating and keeping the temperature until the gelatin and methyl p-hydroxybenzoate are fully dissolved, then adding the liquorice fluid extract, and stirring uniformly for later use;
(3) weighing a prescription dose of dequalinium chloride as a main drug, adding an ethanol solution, heating, stirring and dissolving for later use;
(4) uniformly mixing the solutions obtained in the step (2) and the step (3), then adding the uniformly mixed powder obtained in the step (1), stirring, preparing a soft material and granulating;
(5) after granulation is finished, drying, sieving and granulating;
(6) and (3) uniformly mixing the granules prepared in the step (5) with menthol, essence, magnesium stearate and sodium carboxymethylcellulose, and tabletting.
Preferably, when beta-cyclodextrin is included in the formulation, beta-cyclodextrin is added in the prescribed amount in said step (3).
Preferably, the particle sizes of the sucrose, the mannitol and the dequalinium chloride are all 100-130 mu m.
More preferably, the particle sizes of the sucrose, the mannitol and the dequalinium chloride are all 110-120 mu m.
When the particle size of each solid is 100-130 mu m, the dissolving speed of each prescription in the oral cavity can be accelerated to be equal, and the phenomenon that the surface of the lozenge is slightly pitted due to different dissolving speeds of all the prescriptions to generate non-greasy and unsmooth mouthfeel is avoided, so that the mouthfeel of the dequalinium chloride lozenge is improved. Wherein, when the grain diameters of the sucrose, the mannitol and the dequalinium chloride are all 110-120 mu m, the effect of improving the taste is better.
Preferably, the water in the step (2) is hot water at the temperature of 40-90 ℃. The hot water within the temperature range can ensure that the dissolution is more sufficient, and the gelatin and the methylparaben can be dispersed more uniformly to form better intermolecular interaction and increase the adhesion effect, so that the buccal tablet is not easy to break after being taken in the mouth and can be kept in the oral cavity for a longer time.
Preferably, the volume fraction of the ethanol solution in the step (3) is 50%. The solubility of the dequalinium chloride in an ethanol solution with the volume fraction of 50% is better, so that the distribution of the main components of the prepared dequalinium chloride buccal tablet is more uniform, and the content of the main drug of each dequalinium chloride buccal tablet is ensured to be consistent as much as possible.
The preparation method has the advantages of simple process, low energy consumption and low cost, and the prepared dequalinium chloride buccal tablet has the advantages of uniform main drug content, long buccal time, good taste and good patient compliance.
Detailed Description
Example 1
The preparation method comprises the following steps:
(1) weighing sucrose, mannitol, stearic acid and pigment in the formula parts, crushing, and fully and uniformly mixing;
(2) weighing gelatin and methyl p-hydroxybenzoate according to the prescription amount, adding water for dispersion, heating and keeping the temperature until the gelatin and methyl p-hydroxybenzoate are fully dissolved, then adding the liquorice fluid extract, and stirring uniformly for later use;
(3) weighing a prescription dose of dequalinium chloride as a main drug, adding an ethanol solution, heating, stirring and dissolving for later use;
(4) uniformly mixing the solutions obtained in the step (2) and the step (3), then adding the uniformly mixed powder obtained in the step (1), stirring, preparing a soft material and granulating;
(5) after granulation is finished, drying, sieving and granulating;
(6) and (3) uniformly mixing the granules prepared in the step (5) with menthol, essence, magnesium stearate and sodium carboxymethylcellulose, and tabletting.
Example 2
The preparation method is as in example 1.
Example 3
The preparation method is as in example 1.
Example 4
The preparation method is as in example 1.
Example 5
The preparation method is as in example 1.
Example 6
The grain diameters of the sucrose, the mannitol and the dequalinium chloride are all 100 mu m.
The preparation method comprises the following steps:
(1) preparing the grain sizes of the sucrose, the mannitol and the dequalinium chloride into 100 mu m;
(2) weighing sucrose, mannitol, stearic acid and pigment in the formula parts, crushing, and fully and uniformly mixing;
(3) weighing gelatin and methyl p-hydroxybenzoate according to the prescription amount, adding water for dispersion, heating and keeping the temperature until the gelatin and methyl p-hydroxybenzoate are fully dissolved, then adding the liquorice fluid extract, and stirring uniformly for later use;
(4) weighing a prescription dose of dequalinium chloride as a main drug, adding 50% ethanol solution by volume fraction, heating, stirring and dissolving for later use;
(5) uniformly mixing the solutions obtained in the step (3) and the step (4), adding the uniformly mixed solution into the powder obtained in the step (2), stirring, preparing a soft material and granulating;
(6) after granulation is finished, drying, sieving and granulating;
(7) and (4) uniformly mixing the granules prepared in the step (6) with menthol, essence, magnesium stearate and sodium carboxymethylcellulose, and tabletting.
Example 7
The particle sizes of the sucrose, the mannitol and the dequalinium chloride are all 130 mu m.
The preparation method comprises the following steps:
(1) preparing the grain sizes of the sucrose, the mannitol and the dequalinium chloride into 130 mu m;
(2) weighing sucrose, mannitol, stearic acid and pigment in the formula parts, crushing, and fully and uniformly mixing;
(3) weighing gelatin and methyl p-hydroxybenzoate according to the prescription amount, adding water for dispersion, heating and keeping the temperature until the gelatin and methyl p-hydroxybenzoate are fully dissolved, then adding the liquorice fluid extract, and stirring uniformly for later use;
(4) weighing a prescription dose of dequalinium chloride as a main drug, adding 50% ethanol solution by volume fraction, heating, stirring and dissolving for later use;
(5) uniformly mixing the solutions obtained in the step (3) and the step (4), adding the uniformly mixed solution into the powder obtained in the step (2), stirring, preparing a soft material and granulating;
(6) after granulation is finished, drying, sieving and granulating;
(7) and (4) uniformly mixing the granules prepared in the step (6) with menthol, essence, magnesium stearate and sodium carboxymethylcellulose, and tabletting.
Example 8
The particle sizes of the sucrose, the mannitol and the dequalinium chloride are all 110 mu m.
The preparation method comprises the following steps:
(1) preparing the grain sizes of the sucrose, the mannitol and the dequalinium chloride into 110 mu m;
(2) weighing sucrose, mannitol, stearic acid and pigment in the formula parts, crushing, and fully and uniformly mixing;
(3) weighing gelatin and methyl p-hydroxybenzoate according to the prescription amount, adding hot water at 50-90 ℃ for dispersion, heating and preserving heat until the gelatin and methyl p-hydroxybenzoate are fully dissolved, then adding the liquorice fluid extract, and uniformly stirring for later use;
(4) weighing a prescription dose of dequalinium chloride as a main drug, adding 50% ethanol solution by volume fraction, heating, stirring and dissolving for later use;
(5) uniformly mixing the solutions obtained in the step (3) and the step (4), adding the uniformly mixed solution into the powder obtained in the step (2), stirring, preparing a soft material and granulating;
(6) after granulation is finished, drying, sieving and granulating;
(7) and (4) uniformly mixing the granules prepared in the step (6) with menthol, essence, magnesium stearate and sodium carboxymethylcellulose, and tabletting.
Example 9
The grain sizes of the sucrose, the mannitol and the dequalinium chloride are all 120 mu m.
The preparation process is referred to example 8.
Example 10
The particle sizes of the sucrose, the mannitol and the dequalinium chloride are all 115 mu m.
The preparation method comprises the following steps:
(1) preparing the grain sizes of the sucrose, the mannitol and the dequalinium chloride into 115 mu m;
(2) weighing sucrose, mannitol, stearic acid and pigment in the formula parts, crushing, and fully and uniformly mixing;
(3) weighing gelatin, methyl p-hydroxybenzoate and beta-cyclodextrin according to a prescription amount, adding hot water at 50-90 ℃ for dispersion, heating and preserving heat until the gelatin, the methyl p-hydroxybenzoate and the beta-cyclodextrin are fully dissolved, then adding a liquorice fluid extract, and uniformly stirring for later use;
(4) weighing a prescription dose of dequalinium chloride as a main drug, adding 50% ethanol solution by volume fraction, heating, stirring and dissolving for later use;
(5) uniformly mixing the solutions obtained in the step (3) and the step (4), adding the uniformly mixed solution into the powder obtained in the step (2), stirring, preparing a soft material and granulating;
(6) after granulation is finished, drying, sieving and granulating;
(7) and (4) uniformly mixing the granules prepared in the step (6) with menthol, essence, magnesium stearate and sodium carboxymethylcellulose, and tabletting.
Example 11
The grain diameters of the sucrose, the mannitol and the dequalinium chloride are all 100 mu m.
The preparation process is as in example 10.
Test example 1 measurement of content of active ingredient
The contents of the principal drugs in the dequalinium chloride buccal tablets described in examples 1 to 11 were measured with reference to the method for measuring the contents of the dequalinium chloride buccal tablets (high performance liquid chromatography) described in the second appendix of the 2010 version of the pharmacopoeia.
Comparative example: the commercially available dequalinium chloride buccal tablet is 0.25 mg/tablet.
The buccal time of the buccal tablet is tested according to the method for buccal time of the buccal tablet commonly used in the field. See the following table for specific results of the assay.
| Sample (I) | Dequalinium chloride content (%) | Buccal cavity buccal time (min) |
| Example 1 | 99.5 | 18.3 |
| Example 2 | 99.6 | 18.5 |
| Example 3 | 99.9 | 19.0 |
| Example 4 | 100.1 | 19.2 |
| Example 5 | 100.2 | 19.4 |
| Example 6 | 101.5 | 19.6 |
| Example 7 | 101.8 | 19.8 |
| Example 8 | 102.1 | 20 |
| Example 9 | 102.3 | 20.4 |
| Example 10 | 101.9 | 20.8 |
| Example 11 | 102 | 21.4 |
| Comparative example | 98.6 | 12.8 |
The test data show that the dequalinium chloride buccal tablet prepared by the technical scheme of the invention has high main drug content and good treatment effect; particularly, the dequalinium chloride buccal tablet has longer buccal time, can act on local affected parts of oral cavity or throat more durably, can reduce the frequency of taking medicines by patients, and is more convenient.
In particular, the dequalinium chloride buccal tablets of examples 10 and 11 contain the beta-cyclodextrin in the weight part according to the technical scheme of the invention, so that the time for the dequalinium chloride buccal tablet to be contained in the oral cavity is relatively prolonged, the bitter taste of the principal drug of the dequalinium chloride buccal tablet can be further reduced, the mouthfeel of the dequalinium chloride buccal tablet is improved, and the user can more conform to the dequalinium chloride buccal tablet.
Test example 2 influence of particle size of sucrose, mannitol and dequalinium chloride buccal tablets on mouthfeel
The sucrose, the mannitol and the dequalinium chloride are important components of the dequalinium chloride buccal tablet, and whether the dissolution speeds of the sucrose, the mannitol and the dequalinium chloride buccal tablet are equivalent or not is important to influence the taste of the dequalinium chloride buccal tablet.
On the basis of solving the basic technology, the inventor researches the influence of the grain sizes of the sucrose, mannitol and dequalinium chloride buccal tablets on the taste in order to further improve the taste of the dequalinium chloride buccal tablets and improve the taking compliance of patients. And a number of research analyses according to the invention lead to the following preferred or more preferred solutions:
preferably, the particle sizes of the sucrose, the mannitol and the dequalinium chloride are all 100-130 mu m;
more preferably, the particle sizes of the sucrose, the mannitol and the dequalinium chloride are all 110-120 mu m.
To better illustrate the beneficial effects of the preferred or more preferred embodiments, the following will use the formulation of example 1 as a basic reference to study the differences in taste of the desquinaldium chloride buccal tablets having different particle sizes of sucrose, mannitol and desquinaldium chloride, and the different embodiments are only in the particle sizes of sucrose, mannitol and desquinaldium chloride, and the other factors are the same and the preparation method is the same.
Preparation of 2-1 dequalinium chloride buccal tablet test example
The particle sizes of sucrose, mannitol and dequalinium chloride for each test example are shown in the following table:
2-2 mouthfeel testing
The taste of each test example prepared above was tested according to a conventional method in the medical technical field and classified according to the following grades:
1-no broken particles, no bitter taste and slight degree of astringent feeling in the buccal process;
2-no broken particles, no bitter taste and extremely slight degree of astringent feeling in the buccal process;
3-no broken particles, no bitter taste, very greasy feeling and no astringent feeling in the buccal process.
| Test number | Taste grade |
| 1 | 1 |
| 2 | 1 |
| 3 | 1 |
| 4 | 1 |
| 5 | 2 |
| 6 | 3 |
| 7 | 3 |
| 8 | 2 |
| 9 | 1 |
| 10 | 1 |
According to the test results, the following results can be obtained: the mouth feel grades of the dequalinium chloride buccal tablets in the test examples 5-8 are better than those of the test examples 1-4 and 9-10, the astringency caused by slight pitted surface of the buccal tablets is relatively weaker or basically not existed due to inconsistent dissolution speeds of the components, the smoothness is better, and the mouth feel is greatly improved. Among them, the test examples 6 to 7 had better smoothness, weaker astringency, and better patient compliance.
In conclusion, when the particle sizes of the sucrose, the mannitol and the dequalinium chloride in the dequalinium chloride buccal tablet are all 100-130 μm or the particle sizes of the sucrose, the mannitol and the dequalinium chloride are all 110-120 μm, relatively good or better mouthfeel can be obtained, and the compliance of patients in taking the dequalinium chloride buccal tablet is better.
3. Beta-cyclodextrin improvement of hydration time
Based on the prescription of example 2, the influence of the added beta-cyclodextrin on the buccal tablet of dequalinium chloride is examined according to the principle of single factor control. The experimental data in the section below is explained in detail.
The specific condition of adding beta-cyclodextrin in each test sample in the experiment and the result of testing the incAN _ SNoration time of the corresponding sample in the clubhouse cavity are shown in the following table.
The experimental results show that the corresponding dequalinium chloride buccal tablets have relatively longer buccal time due to the addition of 0.005-0.015 weight part of beta-cyclodextrin in the experimental number D-F, so that the dequalinium chloride buccal tablets can locally act on affected parts for a longer time, and the treatment effect is improved.
The foregoing is considered to represent preferred embodiments of the present invention and not all aspects of the present invention, and all equivalent alterations, modifications and variations which are within the spirit and scope of the invention are intended to be covered thereby.
Claims (8)
1. The dequalinium chloride buccal tablet is characterized by comprising the following components:
the particle sizes of the sucrose, the mannitol and the dequalinium chloride are all 100-130 mu m.
2. The dequalinium chloride buccal tablet according to claim 1 is characterized by comprising the following components:
3. the dequalinium chloride buccal tablet according to claim 1 is characterized by comprising the following components:
4. the dequalinium chloride buccal tablet according to any one of claims 1 to 3, characterized in that the particle size of the sucrose, the mannitol and the dequalinium chloride is 110-120 μm.
5. A method for preparing the dequalinium chloride buccal tablet as claimed in any one of claims 1 to 3, characterized by comprising the following steps:
(1) weighing sucrose, mannitol, stearic acid and pigment in the formula parts, crushing, and fully and uniformly mixing;
(2) weighing gelatin, methyl p-hydroxybenzoate and beta-cyclodextrin according to the prescription amount, adding water for dispersion, heating and keeping the temperature until the gelatin, the methyl p-hydroxybenzoate and the beta-cyclodextrin are fully dissolved, then adding the liquorice fluid extract, and uniformly stirring for later use;
(3) weighing a prescription dose of dequalinium chloride as a main drug, adding an ethanol solution, heating, stirring and dissolving for later use;
(4) uniformly mixing the solutions obtained in the step (2) and the step (3), then adding the uniformly mixed powder obtained in the step (1), stirring, preparing a soft material and granulating;
(5) after granulation is finished, drying, sieving and granulating;
(6) and (3) uniformly mixing the granules prepared in the step (5) with menthol, essence, magnesium stearate and sodium carboxymethylcellulose, and tabletting.
6. The method for preparing dequalinium chloride buccal tablet according to claim 5, wherein the particle size of the sucrose, the mannitol and the dequalinium chloride is 100-130 μm.
7. The method for preparing dequalinium chloride buccal tablet according to claim 6, wherein the particle size of the sucrose, the mannitol and the dequalinium chloride is 110-120 μm.
8. The method for preparing dequalinium chloride buccal tablet according to any one of claims 5-7, characterized in that the volume fraction of ethanol solution in the step (3) is 50%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611042007.5A CN106727369B (en) | 2016-11-21 | 2016-11-21 | Dequalinium chloride buccal tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611042007.5A CN106727369B (en) | 2016-11-21 | 2016-11-21 | Dequalinium chloride buccal tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106727369A CN106727369A (en) | 2017-05-31 |
| CN106727369B true CN106727369B (en) | 2020-01-21 |
Family
ID=58974607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611042007.5A Active CN106727369B (en) | 2016-11-21 | 2016-11-21 | Dequalinium chloride buccal tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727369B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108635334A (en) * | 2018-07-27 | 2018-10-12 | 安徽恒星制药有限公司 | A kind of novel Dequalinium Chloride lozenge and preparation method thereof |
| CN110801437A (en) * | 2019-11-26 | 2020-02-18 | 安徽恒星制药有限公司 | Dequalinium chloride buccal tablet and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1437944A (en) * | 2003-03-07 | 2003-08-27 | 武汉同济明治医药有限公司 | Technology for producing Dekuiluan lozenge |
| CN101048149A (en) * | 2004-10-28 | 2007-10-03 | 兴和株式会社 | Solid pharmaceutical preparation dissolved in oral cavity |
| CN104337786A (en) * | 2014-11-08 | 2015-02-11 | 山东新时代药业有限公司 | Cetyl pyridinium chloride buccal tablet |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3849321B2 (en) * | 1998-10-01 | 2006-11-22 | 井関農機株式会社 | Vehicle refueling device |
-
2016
- 2016-11-21 CN CN201611042007.5A patent/CN106727369B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1437944A (en) * | 2003-03-07 | 2003-08-27 | 武汉同济明治医药有限公司 | Technology for producing Dekuiluan lozenge |
| CN101048149A (en) * | 2004-10-28 | 2007-10-03 | 兴和株式会社 | Solid pharmaceutical preparation dissolved in oral cavity |
| CN104337786A (en) * | 2014-11-08 | 2015-02-11 | 山东新时代药业有限公司 | Cetyl pyridinium chloride buccal tablet |
Non-Patent Citations (1)
| Title |
|---|
| 地喹氯胺含片（普乐津）说明书;https://www.jianke.com/product/57855.html?cxywy;《百度》;20150617;1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106727369A (en) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021120972A1 (en) | Traditional chinese medicine composition for treating deficiency of both qi and blood, preparation method therefor and use thereof | |
| Pattanayak et al. | Formulation development and optimization of medicated lozenges for pediatric use | |
| CN103919920A (en) | Buccal tablet retaining original ecology of wolfberry fruits and preparation process thereof | |
| CN106138129A (en) | A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease | |
| CN106727369B (en) | Dequalinium chloride buccal tablet and preparation method thereof | |
| CN105380918A (en) | Acanthopanax trifoliatus polysaccharide tablet with blood sugar-reducing and health-care functions and preparation method thereof | |
| CN102462713A (en) | Panax notoginseng total saponin nasal in situ gel with phase transition property | |
| CN107569504B (en) | Ambroxol hydrochloride dispersible tablet and preparation method thereof | |
| CN102657778B (en) | Honeysuckle throat clearing tablets and preparation method thereof | |
| CN101461904A (en) | Method for testing Chinese medicinal composition for treating painful swelling of throat and constipation | |
| CN107184555A (en) | A kind of Procaterol Hydrochloride granule and preparation method thereof | |
| CN100444875C (en) | Common cold heat clearing chewing tablet and its preparation method | |
| CN102342949A (en) | Application of phlorhizin in preparation of drug for treating hyperuricemia | |
| CN114129528A (en) | Novel sildenafil citrate preparation with clinical advantages and preparation process and application thereof | |
| CN105726503A (en) | Levofloxacin hydrochloride tablet | |
| CN105596312A (en) | Dimemorfan phosphate capsule composition and preparing method thereof | |
| CN101036687A (en) | Gypenosides dropping pills and the method for preparing the same | |
| CN105145957A (en) | Health herbal tea for treating oral ulcer, preparation method of health herbal tea and detection method | |
| CN104490814A (en) | Zinc gluconate composition chewable tablets and preparation method thereof | |
| CN104013684A (en) | Pelvic inflammation treating tablet and preparation method thereof | |
| CN1872052B (en) | Drop pills of simvastatin, and preparation method | |
| CN103463014B (en) | A kind of α keto acid compound and preparation technology thereof | |
| Rao et al. | Design and Development of Tramadol Hydrochloride Lozenges for Pediatrics | |
| CN1872318B (en) | Drop pills of oil of zedoary turmeric, and preparation method | |
| CN100450489C (en) | Huangyangning drop pills and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |